An earnings miss, a disappointing return on equity, and a decrease in the top-end full-year EPS guidance raised red flags. Did earnings suggest downside ahead for Evergy?
Excellent profit margins, understated future earnings potential, and winning the bidding war for Metsera have injected bullishness. Should you buy Pfizer following the Metsera deal?